Next Article in Journal
Corneal Nerve Abnormalities in Painful Dry Eye Disease Patients
Next Article in Special Issue
Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
Previous Article in Journal
The Role of Uterine Natural Killer Cells on Recurrent Miscarriage and Recurrent Implantation Failure: From Pathophysiology to Treatment
Article

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma

1
Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA 94806, USA
2
Biology and Environmental Science College, Hunan University of Arts and Science, Changde 415000, China
3
Forevertek Biotechnology, Janshan Road, Changsha Hi-Tech Industrial Development Zone, Changsha 410205, China
*
Authors to whom correspondence should be addressed.
Academic Editor: Amedeo Amedei
Biomedicines 2021, 9(10), 1422; https://doi.org/10.3390/biomedicines9101422
Received: 5 August 2021 / Revised: 29 September 2021 / Accepted: 1 October 2021 / Published: 9 October 2021
(This article belongs to the Special Issue State-of-the-Art Immunology and Immunotherapy in USA)
Multiple myeloma (MM) is a hematological cancer caused by abnormal proliferation of plasma cells in the bone marrow, and novel types of treatment are needed for this deadly disease. In this study, we aimed to develop novel CS1 CAR-T cells and bispecific CS1-BCMA CAR-T cells to specifically target multiple myeloma. We generated a new CS1 (CD319, SLAM-7) antibody, clone (7A8D5), which specifically recognized the CS1 antigen, and we applied it for the generation of CS1-CAR. CS1-CAR-T cells caused specific killing of CHO-CS1 target cells with secretion of IFN-gamma and targeted multiple myeloma cells. In addition, bispecific CS1-BCMA-41BB-CD3 CAR-T cells effectively killed CHO-CS1 and CHO-BCMA target cells, killed CS1/BCMA-positive multiple myeloma cells, and secreted IFN-gamma. Moreover, CS1-CAR-T cells and bispecific CS1-BCMA CAR-T cells effectively blocked MM1S multiple myeloma tumor growth in vivo. These data for the first time demonstrate that novel CS1 and bispecific CS1-BCMA-CAR-T cells are effective in targeting MM cells and provide a basis for future clinical trials. View Full-Text
Keywords: chimeric antigen receptor; CAR-T cells; CS1; BCMA; immunotherapy; cell therapy; tumor antigen; multiple myeloma chimeric antigen receptor; CAR-T cells; CS1; BCMA; immunotherapy; cell therapy; tumor antigen; multiple myeloma
Show Figures

Figure 1

MDPI and ACS Style

Golubovskaya, V.; Zhou, H.; Li, F.; Berahovich, R.; Sun, J.; Valentine, M.; Xu, S.; Harto, H.; Sienkiewicz, J.; Huang, Y.; Wu, L. Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma. Biomedicines 2021, 9, 1422. https://doi.org/10.3390/biomedicines9101422

AMA Style

Golubovskaya V, Zhou H, Li F, Berahovich R, Sun J, Valentine M, Xu S, Harto H, Sienkiewicz J, Huang Y, Wu L. Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma. Biomedicines. 2021; 9(10):1422. https://doi.org/10.3390/biomedicines9101422

Chicago/Turabian Style

Golubovskaya, Vita, Hua Zhou, Feng Li, Robert Berahovich, Jinying Sun, Michael Valentine, Shirley Xu, Hizkia Harto, John Sienkiewicz, Yanwei Huang, and Lijun Wu. 2021. "Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma" Biomedicines 9, no. 10: 1422. https://doi.org/10.3390/biomedicines9101422

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop